|
Veterans Administration hospitalization database, Patient Treatment File, and Ou
|
ZIA CP010126 - 00580
|
$39,863
|
$1,993
|
McGlynn, Katherine
|
DCEG (NCI)
|
|
Using game mechanics to improve outcomes among stem cell transplant survivors
|
2R42CA168107-02
|
$616,412
|
$308,206
|
MCLAUGHLIN, JEFFERY
|
RADIANT CREATIVE GROUP, LLC
|
|
Understanding T Cell Rapamycin Resistance
|
ZIA BC 011220
|
$263,739
|
$26,374
|
Fowler, Daniel
|
CCR (NCI)
|
|
The Role of NF-kB in B-Cell Differentiation and Lymphomagenesis
|
5R01CA157660-04
|
$331,240
|
$165,620
|
KLEIN, ULF
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
3P30CA060553-21S1
|
$79,482
|
$795
|
PLATANIAS, LEONIDAS
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
5P30CA060553-21
|
$4,814,560
|
$48,146
|
PLATANIAS, LEONIDAS
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
Survivorship: Mentoring and Bridging Primary Care and Oncology
|
5K05CA160724-05
|
$164,278
|
$82,139
|
OEFFINGER, KEVIN
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Study of the Roles of SDF1 and CXCR4 in Hematopoiesis
|
ZIA BC 010782
|
$371,630
|
$92,907
|
Tosato, Giovanna
|
CCR (NCI)
|
|
Study of Structures of CCR5 and Its Interactions with CCR5 Inhibitors
|
ZIA BC 011109
|
$163,092
|
$8,155
|
Mitsuya, Hiroaki
|
CCR (NCI)
|
|
SPORE in Lymphoma
|
5P50CA126752-09
|
$2,184,999
|
$764,750
|
HESLOP, HELEN
|
BAYLOR COLLEGE OF MEDICINE
|
|
SEER, Registries, and Special Projects
|
ZIA CP010131 - 10560
|
$49,368
|
$4,937
|
Freedman, Daryl
|
DCEG (NCI)
|
|
Roles of Epstein-Barr virus nuclear antigens 2 and LP in B cell proliferation
|
5R01CA170023-03
|
$392,517
|
$196,259
|
KIEFF, ELLIOTT
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Research Management and Support
|
RMS ES 2015
|
$348,215,937
|
$22,000
|
Unknown, Unknown
|
National Cancer Institute
|
|
Regulation of transcription and tumor suppression by MTG family members
|
5R01CA178030-02
|
$364,000
|
$120,120
|
HIEBERT, SCOTT
|
VANDERBILT UNIVERSITY
|
|
Regulation of Exocytosis from Immune Cells
|
ZIA BC 011035
|
$101,641
|
$25,410
|
Roche, Paul
|
CCR (NCI)
|
|
Regulation of EBV Latency by EBNA1
|
5R01CA093606-13
|
$321,273
|
$257,018
|
LIEBERMAN, PAUL
|
WISTAR INSTITUTE
|
|
Registry linkage projects [including Scandinavia, SEER Medicare, other]
|
ZIA CP010150 - 10359
|
$270,757
|
$54,151
|
Engels, Eric
|
DCEG (NCI)
|
|
Radiation Oncology Branch - Radiation Clinic
|
ZID BC 010990
|
$4,728,585
|
$378,287
|
Camphausen, Kevin
|
CCR (NCI)
|
|
Radiation dose- response and second primary cancers of stomach, esophagus, and p
|
ZIA CP010131 - 04134
|
$136,811
|
$20,522
|
Morton, Lindsay
|
DCEG (NCI)
|
|
Preclinical development and clinical monitoring of adoptive immune therapy
|
ZIC BC 011029
|
$337,445
|
$84,361
|
Hakim, Frances
|
CCR (NCI)
|
|
Post-Transcriptional Regulation of Interleukin-7 Receptor Expression
|
ZIA BC 011214
|
$501,835
|
$100,367
|
Park, Jung-Hyun
|
CCR (NCI)
|
|
Plasma and serum biomarkers for Hodgkin lymphoma
|
5R21CA188824-02
|
$178,438
|
$178,438
|
AMBINDER, RICHARD
|
JOHNS HOPKINS UNIVERSITY
|
|
Pharmacokinetic and Pharmacodynamic Modeling of Anticancer Agents
|
ZIC BC 010548
|
$344,293
|
$68,859
|
Figg, William
|
CCR (NCI)
|
|
Optimizing Palliative and End of Life Care for Patients with Cancer
|
5K24CA181253-02
|
$147,306
|
$16,204
|
TEMEL, JENNIFER
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Optimal Antiretroviral Therapy During Bone Marrow Transplant in HIV-1 Infection
|
5K23CA177321-02
|
$161,608
|
$64,643
|
DURAND, CHRISTINE
|
JOHNS HOPKINS UNIVERSITY
|
|
Novel Pathogen Associated Cancers (PQ12)
|
5R01CA170386-04
|
$371,081
|
$74,216
|
GALLOWAY, DENISE
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Novel AHCT Regimen for Advanced Hodgkin Lymphoma using Y-90 anti-CD25 with BEAM
|
1R21CA185875-01A1
|
$207,513
|
$207,513
|
SMITH, EILEEN
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
NCI National Clinical Trials Network-Network Lead Academic Participating Sites
|
5U10CA180836-02
|
$634,750
|
$15,869
|
KINDLER, HEDY
|
UNIVERSITY OF CHICAGO
|
|
Molecularly Targeted Therapy for Lymphoma
|
5K24CA184039-02
|
$174,048
|
$34,810
|
GOPAL, AJAY
|
UNIVERSITY OF WASHINGTON
|
|
Microbial diversity and human malignancy
|
ZIA CP010214 - 10419
|
$322,275
|
$64,455
|
Goedert, James
|
DCEG (NCI)
|
|
Medical Oncology Fellowship Program
|
ZIE BC 010843
|
$4,389,288
|
$219,464
|
Gulley, James
|
CCR (NCI)
|
|
Mechanisms of transcription factor integration at the c-myc promoter
|
ZIA SC 009144
|
$262,697
|
$26,270
|
Levens, David
|
CCR (NCI)
|
|
Mechanisms of MHC Class II Association with Plasma Membrane Microdomains
|
ZIA BC 011033
|
$203,283
|
$50,821
|
Roche, Paul
|
CCR (NCI)
|
|
Lymphoma Studies
|
ZIA SC 006741
|
$522,778
|
$104,556
|
Wilson, Wyndham
|
CCR (NCI)
|
|
Lymphoma Disease Discovery and Definition
|
ZIA SC 000550
|
$599,762
|
$59,976
|
Jaffe, Elaine
|
CCR (NCI)
|
|
LyMB Clinical Trials Team
|
ZID BC 011658
|
$869,062
|
$217,266
|
Waldmann, Thomas
|
CCR (NCI)
|
|
Low dose and low dose-rate cancer risk
|
ZIA CP010132 - 10681
|
$18,399
|
$2,760
|
Little, Mark
|
DCEG (NCI)
|
|
INCREMENTAL SEVERABLE FUNDING FOR THE NCI AT FREDERICK
|
261200800001E
|
$205,925,847
|
$17,432
|
HEIMBROOK, DAVID
|
LEIDOS BIOMEDICAL RESEARCH, INC.
|
|
In Vivo Model of Epstein-Barr Virus Latency
|
5R01CA073507-17
|
$372,677
|
$186,339
|
LONGNECKER, RICHARD
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
Immunotoxin Therapy of Solid and Hematopoietic Tumors: Preclinical Studies
|
ZIA BC 008753
|
$1,758,275
|
$263,741
|
Pastan, Ira
|
CCR (NCI)
|
|
Immunohistochemistry Core Laboratory
|
ZIC BC 011087
|
$683,810
|
$20,514
|
Raffeld, Mark
|
CCR (NCI)
|
|
Immune Regulatory Roles of Suppressor Of Cytokine Signaling (SOCS) Molecules
|
ZIA BC 011215
|
$215,072
|
$21,507
|
Park, Jung-Hyun
|
CCR (NCI)
|
|
Immune reconstitution following autologous and allogeneic stem cell transplant
|
ZIC BC 010934
|
$506,168
|
$101,234
|
Hakim, Frances
|
CCR (NCI)
|
|
IL-2/IL-15 cytokine receptor: implications for cancer therapy and vaccine
|
ZIA SC 004002
|
$1,117,366
|
$223,473
|
Waldmann, Thomas
|
CCR (NCI)
|
|
Human Immune Responses to Tumor Antigens for Cancer Immunotherapy
|
ZIA BC 010598
|
$606,959
|
$30,348
|
Schlom, Jeffrey
|
CCR (NCI)
|
|
Hodgkin's families
|
ZIA CP004410 - 08167
|
$137,951
|
$131,054
|
Goldin, Lynn
|
DCEG (NCI)
|
|
HIV AIDS cancer match, U.S.
|
ZIA CP010150 - 10071
|
$127,100
|
$19,065
|
Engels, Eric
|
DCEG (NCI)
|
|
High dose/high dose rate radiobiological and radioepidemiological data
|
ZIA CP010131 - 10595
|
$31,184
|
$4,678
|
Little, Mark
|
DCEG (NCI)
|
|
Hemopoietic malignancies among persons exposed to low and moderate ionizing radia
|
ZIA CP010170 - 10715
|
$65,250
|
$6,525
|
Little, Mark
|
DCEG (NCI)
|
|
Hematopathology Fellowship
|
ZIE BC 011241
|
$428,401
|
$107,100
|
Jaffe, Elaine
|
CCR (NCI)
|
Total relevant funding to Hodgkins disease for this search: $13,623,610
|